Sign inJoin waitlistJoin the waitlist

CR

Christopher Ryan

Professor of Medicine, School of Medicine · Oregon Health & Science University

Credentials: · · ·

History

Oregon Health & Science University
Present

Hematology and Medical Oncology
University of Chicago Medical Center
1997–2000
Internal Medicine
University of Chicago Medical Center
1994–1997
SUNY Upstate Medical University Coll of Med
1990–1994

Research

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit…
Journal of Clinical Oncology · 2008 · 827 citations
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor:…
Journal of Clinical Oncology · 2008 · 477 citations
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
The Lancet · 2019 · 387 citations

TB
Tomasz Beer
30 papers
CB
Charles Blanke
20 papers
Walter Stadler
18 papers
ES
Elad Sharon
17 papers
NV
Nicholas Vogelzang
17 papers
Razelle Kurzrock
17 papers
Sandip Patel
17 papers
Young Chae
17 papers
Lara Davis
12 papers
UV
Ulka Vaishampayan
9 papers
Mark Agulnik
8 papers
RM
Robert Maki
8 papers

Grants

Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy
National Cancer Institute · U01
PI · $2.9M · Oregon Health & Science University
2011–2017

Clinical trials

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Principal investigator · Completed · Early phase 1
OHSU Knight Cancer Institute
2019–2025
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Principal investigator · Completed · Phase 2
OHSU Knight Cancer Institute
2013–2020
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Principal investigator · Completed · Phase 2
OHSU Knight Cancer Institute
2012–2019
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Principal investigator · Completed · Phase 3
SWOG Cancer Research Network
2011–2025